Arzneimittelforschung 2012; 62(12): 561-565
DOI: 10.1055/s-0032-1327570
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Pharmacokinetics and Safety of Eszopiclone in Healthy Chinese Volunteers

Data from a Single-center, Open-label, Single and Multiple Dose, Randomized, Crossover Pharmacokinetic Study of Eszopiclone under Fasting ConditionsF. Wu1, X. L. Zhao1, M. J. Wei2, S. M. Wang1, H. Zhou1, S. J. Guo1, P. Zhang2
  • 1Department of Clinical Pharmacology, Beijing Tongren Hospital, Capital Medical University, Beijing, China
  • 2Institute of Clinical Pharmacology, Peking University, Beijing, China
Further Information

Publication History

received 28 January 2012

accepted 05 September 2012

Publication Date:
04 October 2012 (eFirst)

Abstract

Objective:

The main objective of this study was to investigate the pharmacokinetic characters of eszopiclone (CAS: 138729-47-2) after single and multiple-dose oral administration in healthy adult Chinese volunteers.

Methods:

In single-dose study, 12 subjects were given oral administrations of 1.5, 3 and 6 mg eszopiclone in an open-label, randomized, crossover fashion. In multiple-dose study, 8 subjects were given 3 mg eszopiclone once daily consecutively for 7 days. Blood samples were collected over 24 h and plasma eszopiclone were determined using a validated liquid chromatography/mass spectrometry (LC/MS/MS) assay. The safety and tolerability of eszopiclone was evaluated by adverse events recording, physical examination, laboratory testing, vital signs, and 12-lead ECG findings.

Results:

The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0–24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h. After multiple-dose administration, the steady-state levels of eszopiclone were achieved by the 4th day, and the main pharmacokinetic parameters were Css_max at 33.43±5.63 ng/ml and AUCss (0–24) at 263.30±51.21 ng*h/ml. The most common adverse event was bitter or abnormal taste. All the adverse events were judged as mild to moderate and resolved without any medication.

Conclusion:

The pharmacokinetic character of eszopiclone is linear and dose-proportional over the range of 1.5–6 mg. The systemic exposure does not accumulate with once-daily administrations. Eszopiclone appears to have good safety and is well tolerated.